The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure.
Andrew Jacob Brenner
No relevant relationships to disclose
Jessica D Sun
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
John Floyd
No relevant relationships to disclose
Charles P Hart
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Clarence Eng
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Stew Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Lisa Fichtel
No relevant relationships to disclose
Aleksandra Gruslova
No relevant relationships to disclose
Alessia Lodi
No relevant relationships to disclose
Stefano Tiziani
No relevant relationships to disclose